Corcept Therapeutics

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Corcept Therapeutics sits in the top decile of US sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count).

54 total trials 6 currently recruiting 37 completed early-phase tilt top decile by trial count

Corcept Therapeutics: 54 sponsored US clinical trials, 6 recruiting.

Corcept Therapeutics sponsors 54 registered US clinical trials on ClinicalTrials.gov, 6 of them currently recruiting, and 37 completed. 12 of these trials are in Phase 3-4 (later-stage) and 37 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Cushing Syndrome, with 3 trials.

Top-decile sponsor footprint

Corcept Therapeutics ranks in the top decile of sponsors by registered trial count (#351 of 15,742 sponsors by registered trial count). Volume at this scale usually reflects a long institutional pipeline, read phase tilt and therapeutic areas below before treating it as current-year activity.

Trial completion reliability score

D 50/100

37 of 44 decided trials (Completed vs. Terminated on ClinicalTrials.gov) reached their planned completion (84.1%), vs. national p10 68.4% / p90 100% among 1,234 sponsors with at least 10 decided trials. Still-open trials (Recruiting, Active-not-recruiting, Not-yet-recruiting) are excluded since they have not reached an outcome yet.

Open and recent trials

54 total, page 2 of 2

COMPLETED Phase 3

A United States Extension Study of Corlux for Recurrent Psychotic Symptoms in Psychotic Major Depression

NCT00208156
COMPLETED Phase 3

A United States Study of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00130676
COMPLETED Phase 3

A United States Study of the Safety and Tolerability of Corlux for Psychotic Symptoms in Psychotic Major Depression

NCT00128479
TERMINATED Phase 2

Mifepristone as Adjunctive Therapy in Alzheimer's Disease

NCT00105105
← Previous Page 2 of 2

Phase Distribution

PhaseTrial count
Phase 1 26
Phase 2 11
Phase 3 11
Phase 4 1

Therapeutic Areas

Cushing Syndrome 3
Non-alcoholic Steatohepatitis (NASH) 2
Metabolic Dysfunction-Associated Steatohepatitis (MASH) 2
Peritoneal Neoplasms 2
Neoplasms 2
Cushing's Syndrome 1
Ovarian Neoplasm 1
Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) 1
Hypercortisolism 1
Non-Alcoholic Fatty Liver Disease (NAFLD) 1

What is open in the Corcept Therapeutics pipeline

6 recruiting of 54 indexed (11% open); 37 completed (69%).

Phase mix: 12 late (III/IV) vs 37 early (I/II) (early-phase heavy).

Top condition: Cushing Syndrome (3 trials), 9 others listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Corcept Therapeutics: open-pipeline peers nationwide

Peers matched on 54 registered trials and 11% open enrollment, not the therapeutic-area sidebar.

Corcept Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 0102030405060 0%10%20%30% Total trials Recruiting share Corcept TherapeuticsAdventHealth Translational Research InstituteAuburn UniversityBrooke Army Medical CenterPharmacyclicsADC Therapeutics S.A.Adrian VellaAIDS Malignancy ConsortiumAmylyx Pharmaceuticals
Corcept Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Corcept Therapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 54 trials (± recruiting share)

Sponsors near 11% open enrollment (± trial volume)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Corcept Therapeutics page

54 registered trials is a research-attention snapshot, not an endorsement of Corcept Therapeutics or any single study.

  • 6 of Corcept Therapeutics's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • Cushing Syndrome is the condition Corcept Therapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Cushing Syndrome trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Corcept Therapeutics pipeline card: 54 registered trials from official public datasets.Report a data error.